Tokyo, Japan

Seiji Sakata

USPTO Granted Patents = 3 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Seiji Sakata: Innovator in Cancer Research

Introduction

Seiji Sakata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly through his innovative patents. With a total of three patents to his name, Sakata is recognized for his work in identifying novel causative genes of cancer.

Latest Patents

One of his latest patents focuses on fusions and methods for detecting them. This invention aims to reveal a polynucleotide that serves as a novel causative gene of cancer. Based on this finding, the patent provides a method for detecting the polynucleotide or a polypeptide encoded by it. Additionally, it includes a kit and a primer set for detection, a method for screening substances that inhibit the polypeptide, and a pharmaceutical composition for cancer treatment containing the inhibiting substance. The detection method can identify a BRAF fusion protein or a fusion gene encoding the fusion protein, as well as PXN or GMDS fusion proteins in digestive organ-derived samples from subjects.

Career Highlights

Seiji Sakata is affiliated with the Japanese Foundation for Cancer Research, where he continues to advance his research and innovations. His work has the potential to significantly impact cancer diagnostics and treatment.

Collaborations

Sakata collaborates with notable colleagues, including Kengo Takeuchi and Yuki Togashi, who contribute to his research efforts and innovations in the field.

Conclusion

Seiji Sakata's contributions to cancer research through his innovative patents highlight his role as a key inventor in the medical field. His work not only advances scientific understanding but also offers potential solutions for cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…